Use of 3,4-Dideoxykanamycin B (DKB) in Various Infections
A new antibiotic, 3′,4′-dideoxykanamycin B, discovered by Prof. Umezawa, and abbreviated as DKB, was synthetized on the theory that its mechanism was not apt to succumb to inactivation by bacilli resistant to kanamycin B. Clinical use of DKB, with its commercial preparation named ‘Panimycin’, was started in January of this year following the acceptance by the Ministry of Welfare of the findings on the animal toxicity, teratogenicity, and human pharmacology of the drug and on double blind clinical trials.
KeywordsPseudomonas Aeruginosa Klebsiella Pneumoniae Pulmonary Tuberculosis Double Blind Clinical Trial Complicated Urinary Tract Infection
Unable to display preview. Download preview PDF.